Praxis Precision Medicines
PRAX
111 hedge funds and large institutions have $971M invested in Praxis Precision Medicines in 2024 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 7 closing their positions.
729% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 7
443% more capital invested
Capital invested by funds: $179M → $971M (+$792M)
200% more funds holding in top 10
Funds holding in top 10: 3 → 9 (+6)
117% more call options, than puts
Call options by funds: $2.95M | Put options by funds: $1.36M
85% more funds holding
Funds holding: 60 → 111 (+51)
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
26.5% more ownership
Funds ownership: 93.73% → 120.24% (+27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$37.2M |
| 2 |
PA
Perceptive Advisors
New York
|
+$36.9M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$30.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$29.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$11.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.03M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$7.07M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.81M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$6.38M |
PRAX Hedge Fund Activity: Q1 2024 in Review
111 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2024, worth a combined $971M — up 443% from $179M a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new PRAX positions and 7 closed out — a net gain of 51 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $37.2M. The largest seller was Bank of America, cutting an estimated $11.7M.
- 111 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2024, up from 60 in Q4 2023.
- Funds reported $971M of Praxis Precision Medicines stock for Q1 2024, up 443% quarter-over-quarter.
- 58 funds opened new Praxis Precision Medicines positions in Q1 2024 and 7 closed out, a net change of +51 holders.
- The largest Praxis Precision Medicines buyer in Q1 2024 was RA Capital Management, an estimated $37.2M added.
- The largest Praxis Precision Medicines seller in Q1 2024 was Bank of America, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2024.